Emergency Department-Initiated Buprenorphine: A New Paradigm for OUD Engagement
The opioid crisis remains one of the most pressing public health challenges in the United States, with the emergency department (ED) often serving as the primary, and sometimes only, point of contact for individuals with untreated opioid use disorder (OUD). While the initiation of sublingual buprenorphine in the ED has become a standard of care for many institutions, barriers such as the need for significant withdrawal symptoms prior to induction and the logistical challenges of daily dosing persist. The ED INNOVATION trial, recently published in JAMA, provides critical evidence on the efficacy and safety of a 7-day extended-release injectable buprenorphine formulation as an alternative to traditional sublingual treatment.
Highlights of the ED INNOVATION Trial
The multicenter randomized clinical trial compared the impact of ED-initiated 7-day extended-release (ER) injectable buprenorphine versus sublingual (SL) buprenorphine on treatment engagement and patient-centered outcomes. The key highlights include:
1. Engagement Equivalence: There was no significant difference in treatment engagement at 7 days between the ER injectable group (40.5%) and the SL group (38.5%).
2. Safety Profile: Precipitated withdrawal was remarkably rare (<1%) in both groups, despite a 76% prevalence of fentanyl in the patient population.
3. Craving and Use: Patients receiving the injectable formulation reported significantly lower craving scores and fewer days of illicit opioid use over the first week.
4. Patient Satisfaction: The injectable group reported higher overall satisfaction with their treatment compared to those receiving sublingual prescriptions.
Background: Overcoming Barriers to Buprenorphine Initiation
Traditional buprenorphine initiation often requires patients to reach a moderate level of withdrawal (typically a Clinical Opiate Withdrawal Scale [COWS] score of 8 or higher) to avoid precipitated withdrawal. This requirement can be a significant deterrent for patients in the ED who are already in distress. Furthermore, the reliance on daily sublingual dosing introduces risks of non-adherence, diversion, or accidental exposure.
Extended-release injectable formulations offer a potential solution by providing a steady therapeutic dose over several days. One of the theoretical advantages of the 7-day ER formulation used in this study is its ability to be administered at lower levels of withdrawal (COWS score of 4 or higher), potentially expanding the window of opportunity for ED clinicians to intervene.
Study Design: The ED INNOVATION Randomized Clinical Trial
The trial was conducted across 29 EDs in the United States between July 2020 and August 2024. It enrolled 2,000 adult patients with untreated OUD and a COWS score of 4 or higher. Participants were randomized into two groups:
The Extended-Release (ER) Group
Patients received a 24-mg injection of extended-release buprenorphine, which is pharmacologically equivalent to approximately 16 mg/day of sublingual buprenorphine. This dose provides therapeutic coverage for 7 days.
The Sublingual (SL) Group
Patients received a 7-day prescription for 16 mg/day of SL buprenorphine. If their initial COWS score was 8 or higher, they received their first 8-mg dose in the ED; if it was between 4 and 7, they were provided with self-administration instructions for home induction once withdrawal symptoms worsened.
Both groups received a scheduled follow-up appointment for ongoing OUD medication within 7 days of their ED visit. The primary endpoint was engagement in OUD treatment on day 7.
Primary Results: Treatment Engagement at 7 and 30 Days
The study found that the adjusted proportion of engagement in OUD treatment at 7 days was 40.5% for the ER injectable group and 38.5% for the SL group. The adjusted difference of 1.6% (95% CI, -2.8% to 6.0%) did not meet the criteria for a statistically significant difference, suggesting that both methods are equally effective at bridging patients to their first follow-up appointment.
By day 30, the engagement rates remained similar between the two groups, with 43.8% in the ER group and 44.9% in the SL group (adjusted difference, -1.5%; 95% CI, -6.2% to 3.2%). These findings indicate that while the injectable formulation provides a different delivery mechanism, the long-term retention in care depends on factors beyond the initial formulation used in the ED.
Secondary Outcomes: Craving, Illicit Use, and Patient Satisfaction
While the primary endpoint of engagement was similar, several secondary outcomes favored the extended-release injectable formulation.
At the 7-day mark, patients in the ER group reported lower mean craving scores (26.5 vs. 30.2 on a 100-point scale). Furthermore, the ER group reported fewer days of illicit opioid use during the first week (adjusted ratio of means, 0.77; 95% CI, 0.68-0.95). These data suggest that the steady-state plasma levels achieved by the injection may provide superior symptom control compared to the peaks and troughs associated with daily sublingual dosing.
Patient satisfaction was also significantly higher in the ER group. On a scale of 1 to 5, the ER group had an adjusted mean difference of 0.13 higher than the SL group. This preference may stem from the convenience of not having to manage a daily medication regimen or a paper prescription immediately following an ED visit.
Clinical Safety: Addressing the Fentanyl Challenge
A major concern among clinicians in the modern era of addiction medicine is the high prevalence of illicitly manufactured fentanyl. Fentanyl’s high potency and lipophilic nature have been associated with a perceived increased risk of precipitated withdrawal during buprenorphine induction.
The ED INNOVATION trial provides reassuring data on this front. Despite 76% of the participants testing positive for fentanyl, precipitated withdrawal events were extremely rare: 0.6% (6 patients) in the ER group and 0.8% (8 patients) in the SL group. Overdose events within 30 days were also low and identical between groups, occurring in 2.3% of participants (18 in each group).
Expert Commentary and Clinical Implications
From a clinical perspective, the results of the ED INNOVATION trial support the use of injectable buprenorphine as a viable, safe, and effective option for ED-initiated OUD treatment. The ability to initiate treatment at a lower COWS score (4-7) without a high risk of precipitated withdrawal is a significant advancement.
For many high-risk patients—such as those with housing instability, those who may lose their prescriptions, or those who find daily dosing difficult—the 7-day injectable formulation provides a ‘safety net’ of therapeutic coverage. It ensures that the patient leaves the hospital with a week’s worth of medication already on board, potentially reducing the immediate pressure of pharmacy logistics and self-management.
However, the lack of difference in 7-day engagement also highlights that the medication formulation is only one piece of the puzzle. The ‘warm handoff’ to outpatient clinics and the availability of low-barrier follow-up care remain the most critical factors in long-term treatment success.
Conclusion: Expanding the Toolkit for Emergency Clinicians
The ED INNOVATION trial demonstrates that 7-day extended-release injectable buprenorphine is a robust alternative to sublingual formulations. While it does not significantly increase the rate of engagement compared to the current standard of care, its benefits in reducing craving, decreasing illicit use, and improving patient satisfaction make it a valuable tool in the emergency medicine armamentarium. Most importantly, the study confirms that both injectable and sublingual buprenorphine can be safely initiated in the ED, even in communities where fentanyl use is predominant.
Funding and Trial Registration
This study was supported by the National Institute on Drug Abuse (NIDA) Clinical Trials Network. ClinicalTrials.gov Identifier: NCT04225598.
